Miragen Therapeutics - MGEN Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$37.48
▲ +0.39 (1.05%)
Get New Miragen Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MGEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MGEN

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Miragen Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $37.48.

This chart shows the closing price for MGEN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Miragen Therapeutics. This rating has held steady since December 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/16/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/14/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/12/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/13/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/11/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/9/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/8/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/31/2020OppenheimerReiterated RatingBuy$5.00 ➝ $37.00N/A
12/15/2020JMP SecuritiesInitiated CoverageOutperformLow
11/24/2020WedbushReiterated RatingOutperformLow
10/6/2020HC WainwrightDowngradeBuy ➝ NeutralHigh
8/17/2020WedbushReiterated RatingBuy$6.00High
8/10/2020Jefferies Financial GroupReiterated RatingBuyHigh
7/24/2020WedbushReiterated RatingBuy$6.00Low
7/21/2020Brookline Capital ManagementInitiated CoverageBuy$6.00High
6/23/2020WedbushReiterated RatingBuy$6.00Low
5/13/2020WedbushReiterated RatingBuy$6.00Medium
5/8/2020HC WainwrightReiterated RatingBuyMedium
3/12/2020WedbushReiterated RatingBuy$8.00High
1/30/2020WedbushReiterated RatingBuy$8.00 ➝ $10.00High
1/23/2020WedbushReiterated RatingBuy$8.00High
12/12/2019WedbushReiterated RatingPositive ➝ Buy$24.00 ➝ $8.00Low
12/12/2019Robert W. BairdDowngradeOutperform ➝ NeutralHigh
12/2/2019HC WainwrightReiterated RatingBuy$3.00High
8/19/2019HC WainwrightInitiated CoverageBuy$3.00High
5/21/2019WedbushReiterated RatingBuy$24.00Low
4/29/2019WedbushReiterated RatingOutperform$24.00High
3/18/2019WedbushReiterated RatingOutperform ➝ Outperform$22.00 ➝ $24.00High
1/4/2019Robert W. BairdInitiated CoverageOutperform ➝ OutperformHigh
12/31/2018B. RileyInitiated CoverageBuy ➝ Buy$18.50 ➝ $18.50High
10/8/2018WedbushReiterated RatingOutperform$19.00Medium
8/8/2018WedbushReiterated RatingBuy$19.00High
6/7/2018WedbushReiterated RatingBuyLow
5/18/2018WedbushReiterated RatingOutperform$19.00Low
4/30/2018WedbushReiterated RatingOutperform$19.00Low
4/9/2018CowenReiterated RatingHoldMedium
3/29/2018Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$14.00Medium
3/28/2018WedbushReiterated RatingOutperform$19.00Medium
3/22/2018Deutsche Bank AktiengesellschaftInitiated CoverageBuy$15.00Medium
3/20/2018WedbushReiterated RatingOutperformMedium
3/9/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$19.00Low
(Data available from 2/7/2018 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/12/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/11/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/9/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/9/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/8/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/7/2023

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Miragen Therapeutics logo
Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.
Read More

Today's Range

Now: $37.48
Low: $36.55
High: $38.00

50 Day Range

MA: $17.69
Low: $14.34
High: $23.01

52 Week Range

Now: $37.48
Low: $4.66
High: $34.05

Volume

354,232 shs

Average Volume

134,027 shs

Market Capitalization

$146.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.66

Frequently Asked Questions

What sell-side analysts currently cover shares of Miragen Therapeutics?

The following Wall Street analysts have issued reports on Miragen Therapeutics in the last twelve months:
View the latest analyst ratings for MGEN.

What is the current price target for Miragen Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Miragen Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Miragen Therapeutics in the next year.
View the latest price targets for MGEN.

What is the current consensus analyst rating for Miragen Therapeutics?

Miragen Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for MGEN.

What other companies compete with Miragen Therapeutics?

Other companies that are similar to Miragen Therapeutics include Celcuity, DermTech, Personalis, MDxHealth and Genetron. Learn More about companies similar to Miragen Therapeutics.

How do I contact Miragen Therapeutics' investor relations team?

Miragen Therapeutics' physical mailing address is 6200 LOOKOUT ROAD, BOULDER CO, 80301. The medical research company's listed phone number is 720-643-5200 and its investor relations email address is [email protected] The official website for Miragen Therapeutics is www.signalgenetics.com. Learn More about contacing Miragen Therapeutics investor relations.